Suvorexant and Lemborexant for Insomnia

Sleep and Wakefulness Peptides

3 FDA-Approved DORAs

Suvorexant (2014), lemborexant (2019), and daridorexant (2022) are the three FDA-approved dual orexin receptor antagonists for insomnia, representing a fundamentally different approach from sedative-hypnotics.

Jaszberenyi et al., Pharmacological Reviews, 2024

Jaszberenyi et al., Pharmacological Reviews, 2024

View as image

Every existing sleep drug before 2014 worked by amplifying inhibition: benzodiazepines, Z-drugs (zolpidem, zaleplon), barbiturates, and antihistamines all enhance GABAergic or histaminergic suppression of brain activity. They sedate the brain into sleep. Dual orexin receptor antagonists (DORAs) work through the opposite logic: instead of adding inhibition, they remove excitation. By blocking the orexin (hypocretin) peptide system that actively maintains wakefulness, DORAs allow sleep to occur through its natural mechanisms without pharmacologically sedating the brain.

Three DORAs are now FDA-approved: suvorexant (Belsomra, 2014), lemborexant (Dayvigo, 2019), and daridorexant (Quviviq, 2022). All three block both orexin receptor subtypes (OX1R and OX2R), but they differ in pharmacokinetics, receptor binding profiles, and clinical data. This article covers the clinical trial evidence for each, how they compare, and what their mechanism reveals about the peptide biology of sleep. For the orexin system itself, see Orexin/Hypocretin: The Wakefulness Peptide (and What Happens When It's Missing).

The orexin wakefulness signal

Orexin-A (33 amino acids) and orexin-B (28 amino acids) are neuropeptides produced exclusively by a cluster of approximately 50,000-80,000 neurons in the lateral hypothalamus. Despite this small cell population, orexin neurons project to virtually every major arousal center in the brain: the locus coeruleus (norepinephrine), dorsal raphe (serotonin), tuberomammillary nucleus (histamine), ventral tegmental area (dopamine), and basal forebrain (acetylcholine).

Jaszberenyi et al. (2024) published a comprehensive review of the orexin/hypocretin system as a peptidergic regulator of vigilance, detailing how orexin neurons function as a master switch for the ascending arousal system. During wakefulness, orexin neurons fire continuously, maintaining arousal center activity. During sleep, orexin neurons are silent, allowing the ventrolateral preoptic area's inhibitory (GABAergic/galaninergic) neurons to suppress the arousal centers.^[1]

Orexin acts through two receptor subtypes: OX1R (selective for orexin-A) and OX2R (activated by both orexin-A and orexin-B). OX2R appears more critical for sleep-wake regulation; OX1R plays a larger role in reward, stress, and autonomic functions. Both are G protein-coupled receptors that increase neuronal excitability when activated.

The most dramatic demonstration of orexin's importance is narcolepsy type 1, which is caused by autoimmune destruction of orexin-producing neurons. Without orexin, patients cannot maintain stable wakefulness and experience sudden sleep attacks, cataplexy (muscle weakness triggered by emotions), and disrupted nocturnal sleep. DORAs pharmacologically mimic this loss of orexin signaling, but temporarily and reversibly, to promote sleep.

For the arousal-promoting neuropeptide that works alongside orexin, see Neuropeptide S: The Arousal Peptide That Keeps You Alert. For the sleep-promoting peptide pillar article, see Galanin: The Underappreciated Sleep-Promoting Peptide.

Suvorexant (Belsomra): the first DORA

Suvorexant was approved in 2014 based on two pivotal phase 3 trials (Study 028 and Study 029) enrolling a combined total of approximately 2,000 adults with primary insomnia.

Efficacy

In the pivotal trials, suvorexant 20 mg (recommended dose for most adults) improved three co-primary endpoints vs placebo:

• Subjective time to sleep onset (sTSO): reduced by approximately 8-10 minutes
• Subjective wake after sleep onset (sWASO): reduced by approximately 16-23 minutes
• Polysomnographic measures (objective sleep onset latency and WASO): also significantly improved

The effect sizes were modest compared to the subjective experience patients reported. This discrepancy between measured sleep improvement and perceived benefit is common across insomnia treatments and reflects the difficulty of quantifying sleep quality with single metrics.

Safety profile

Suvorexant's side effects reflect orexin blockade rather than CNS depression:

• Next-morning somnolence: the most common adverse event (7% at 20 mg vs 3% placebo), consistent with residual orexin antagonism from the drug's relatively long half-life (approximately 12 hours)
• Sleep paralysis: rare but reported, consistent with the drug mimicking narcoleptic pathophysiology
• Hypnagogic/hypnopompic hallucinations: rare, also narcolepsy-like
• No respiratory depression: a major advantage over benzodiazepines and opioids, making suvorexant safer for patients with obstructive sleep apnea
• No tolerance or rebound insomnia in trials up to 12 months

Beyond insomnia

Huhn et al. (2022) tested suvorexant in patients undergoing buprenorphine-assisted opioid taper. Suvorexant ameliorated sleep disturbance (a primary complaint during withdrawal), reduced opioid withdrawal symptoms, and decreased craving. This application leverages the known connection between orexin signaling and the reward system: orexin neurons project to and activate dopaminergic circuits involved in drug seeking.^[2]

Cohen et al. (2020) reviewed the broader significance of the orexinergic system in modulating stress-related responses, providing context for why blocking orexin may benefit conditions beyond insomnia where stress and arousal are pathologically elevated.^[3]

Lemborexant (Dayvigo): the second-generation DORA

Lemborexant was approved in 2019 based on the SUNRISE-1 (objective PSG measures) and SUNRISE-2 (subjective measures, 12-month safety) trials.

Key differences from suvorexant

Shorter half-life: Lemborexant has a half-life of approximately 17-19 hours at steady state but reaches peak concentration faster (1-3 hours) than suvorexant. The faster onset may improve sleep initiation, while the long terminal half-life maintains sleep through the night.

Receptor binding: Lemborexant has a more balanced OX1R/OX2R antagonism compared to suvorexant, which is more OX2R-preferring. Whether this pharmacological distinction produces clinically meaningful differences is debated.

Efficacy

In SUNRISE-1, lemborexant 5 mg and 10 mg were both superior to placebo for the primary endpoint (sleep efficiency measured by PSG). In a head-to-head comparison arm within the same trial, lemborexant 10 mg was superior to zolpidem extended-release 6.25 mg for sleep maintenance in the second half of the night, a period where Z-drugs often lose effectiveness.

SUNRISE-2 provided 12-month data confirming sustained efficacy without tolerance development. The 5 mg dose was effective for most patients, with 10 mg available for those needing greater effect.

Network meta-analysis data

A 2025 network meta-analysis comparing all three DORAs across available trial data found:

• Subjective sleep onset: lemborexant 10 mg was most effective
• Subjective total sleep time: daridorexant 50 mg was most effective
• Wake after sleep onset: lemborexant showed the greatest reduction
• Safety: all three DORAs were associated with higher somnolence rates vs placebo, but serious adverse events were rare across all agents

Daridorexant (Quviviq): the newest DORA

Daridorexant, approved in 2022, was developed with specific attention to next-day functioning, an outcome not formally assessed in the suvorexant and lemborexant trials.

Design advantages

Daridorexant has a half-life of approximately 8 hours, the shortest of the three DORAs. This was a deliberate design choice to minimize next-morning somnolence while maintaining overnight efficacy. The Phase 3 trials (Study 301 and 302) included daytime functioning as a secondary endpoint, measured by the Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ).

Results showed that daridorexant 50 mg improved both nighttime sleep measures and daytime functioning compared to placebo, a dual-endpoint achievement that neither suvorexant nor lemborexant demonstrated in their registration trials (though this may reflect trial design differences rather than drug differences).

DORAs vs traditional sleep medications

The mechanistic distinction between DORAs and traditional hypnotics has practical clinical consequences.

No respiratory depression. Benzodiazepines and Z-drugs suppress respiratory drive, making them dangerous in patients with sleep apnea, COPD, or obesity hypoventilation syndrome. DORAs do not affect respiratory function at therapeutic doses because they do not engage GABAergic inhibition. This safety advantage is particularly relevant given the high overlap between insomnia and sleep-disordered breathing in obese populations.

Preserved sleep architecture. Benzodiazepines suppress REM sleep and alter sleep stage distribution. DORAs maintain normal sleep architecture, including REM sleep, slow-wave sleep, and natural stage transitions. This may contribute to better subjective sleep quality, though direct comparisons on this endpoint are limited.

No tolerance. Benzodiazepine tolerance develops within weeks, requiring dose escalation for continued effect. Suvorexant and lemborexant trials of up to 12 months showed no efficacy decline over time. This makes DORAs more suitable for the chronic insomnia that affects most patients with insomnia disorder.

No withdrawal syndrome. Abrupt benzodiazepine discontinuation can cause rebound insomnia, anxiety, and seizures. DORA discontinuation studies showed no rebound insomnia or withdrawal symptoms, consistent with the drugs' mechanism (removing a wakefulness signal rather than creating a dependence-prone inhibitory state).

Lower abuse potential. DORAs are Schedule IV controlled substances (same as benzodiazepines), but abuse liability studies showed lower subjective drug-liking scores than zolpidem. The subjective experience of orexin blockade is sleepiness, not euphoria.

Mohammadkhani et al. (2024) reviewed the broader contribution of hypothalamic orexin circuits to motivation and reward pathology, providing context for why DORA abuse potential is lower: blocking orexin reduces rather than enhances reward signaling.^[4]

The metabolic connection

Orexin signaling extends well beyond sleep-wake regulation. Katzman et al. (2022) reviewed the orexin system's role in hedonic eating, noting that orexin neurons are activated by food cues and contribute to food-seeking behavior. Blocking orexin may therefore have secondary effects on appetite and eating behavior, though clinical insomnia trials have not reported weight changes as a consistent finding.^[5]

Teske et al. (2012) documented orexin's role in energy expenditure, showing that orexin-A increases non-exercise activity thermogenesis (NEAT). Chronic orexin antagonism could theoretically reduce energy expenditure, though no metabolic side effects have been reported in DORA trials.^[6]

Mavanji et al. (2022) reviewed the interconnection between orexin, serotonin, and energy balance, demonstrating that orexin neurons integrate sleep, feeding, and metabolic signals into a unified arousal-metabolism system.^[7]

Kakizaki et al. (2019) showed that the two orexin receptor subtypes play differential roles in obesity: OX1R is more involved in feeding behavior while OX2R is more involved in energy expenditure. This has implications for selective vs dual orexin receptor antagonism in different patient populations.^[8]

For the connection between growth hormone secretion and sleep architecture, see Growth Hormone Peptides and Sleep Quality: The Deep Sleep Connection.

Orexin agonists: the opposite direction

While DORAs block orexin for insomnia, there is parallel interest in orexin agonists for narcolepsy (restoring the missing wake signal). Karhu et al. (2018) developed stapled truncated orexin peptides as orexin receptor agonists, demonstrating that peptide-based orexin replacement is feasible. These agonists face the delivery challenge of crossing the blood-brain barrier, a problem that small-molecule DORAs avoid.^[9]

This bidirectional pharmacology, blocking orexin for insomnia and replacing it for narcolepsy, validates the orexin system as a central node in sleep-wake regulation and confirms that both gain-of-function and loss-of-function approaches have therapeutic potential.

The Bottom Line

Dual orexin receptor antagonists represent a mechanistically distinct class of insomnia treatments. By blocking the neuropeptide signal that maintains wakefulness rather than sedating the brain, DORAs preserve normal sleep architecture, avoid respiratory depression, and do not produce tolerance or withdrawal. Three are FDA-approved: suvorexant (longest track record), lemborexant (best sleep maintenance data), and daridorexant (shortest half-life, best daytime functioning data). A 2025 network meta-analysis found all three effective with differentiated profiles. Beyond insomnia, DORA applications in substance use disorders and the metabolic implications of chronic orexin blockade are active research areas.

Frequently Asked Questions

How do orexin antagonists work for insomnia?

Orexin antagonists block the binding of orexin-A and orexin-B to their receptors (OX1R and OX2R) on arousal-promoting neurons throughout the brain. Orexin normally maintains wakefulness by keeping these neurons active. Blocking orexin signaling allows sleep-promoting circuits to take over naturally, producing sleep without the pharmacological sedation caused by benzodiazepines or Z-drugs. The effect is temporary, lasting the duration of drug exposure.

Which is better, suvorexant or lemborexant?

Both are effective for insomnia. A 2025 network meta-analysis found lemborexant 10 mg most effective for reducing time to fall asleep and wake after sleep onset, while suvorexant 20 mg had comparable overall efficacy. Lemborexant has a faster onset of action. Neither has shown tolerance over 12 months. The choice often depends on individual response and whether next-morning somnolence (slightly more common with suvorexant's longer half-life) is a concern.

Do orexin antagonists cause next-day drowsiness?

Next-morning somnolence is the most common side effect of DORAs, reported in 5-10% of patients depending on dose and agent. Suvorexant (half-life approximately 12 hours) has a higher somnolence rate than daridorexant (half-life approximately 8 hours), which was specifically designed to minimize this effect. Taking DORAs only when a full night of sleep is possible (7+ hours) reduces next-day residual effects.

Are orexin antagonists addictive?

DORAs have lower abuse potential than benzodiazepines and Z-drugs. Abuse liability studies showed lower subjective drug-liking scores for suvorexant compared to zolpidem. DORAs do not produce euphoria because blocking orexin reduces rather than enhances reward signaling. They are classified as Schedule IV controlled substances, but clinical trials up to 12 months showed no tolerance, dose escalation, or withdrawal symptoms upon discontinuation.

Can orexin antagonists be used with sleep apnea?

DORAs do not suppress respiratory drive, unlike benzodiazepines and opioids. This makes them a safer option for patients with obstructive sleep apnea who also have insomnia. Clinical trials did not exclude mild-to-moderate sleep apnea patients, and no respiratory adverse events were reported. This is a direct consequence of the mechanism: blocking a wakefulness neuropeptide does not engage the GABAergic inhibition that suppresses breathing.

What is the newest orexin antagonist for sleep?

Daridorexant (Quviviq), approved in January 2022, is the newest FDA-approved DORA. It was designed with an 8-hour half-life to minimize next-morning residual effects. Its phase 3 trials uniquely included daytime functioning as a secondary endpoint, showing improvement in both sleep and next-day performance at the 50 mg dose. It is available in 25 mg and 50 mg doses.